TABLE 30

Plasma Product	Pre-Lyo FIB (mg/dL)	Post-Lyo FIB (mg/dL)	4 days at 40° C. FIB (mg/dL)	5 days at 40° C. FIB (mg/dL)	6 days at 40° C. FIB (mg/dL)
Control	194.5 ± 53.033	196.0 ± 49.497	185.5 ± 40.305	179.5 ± 43.134	172.5 ± 37.477
+8 mM NH_4SO_4	196.0 ± 46.669	194.5 ± 41.719	187.5 ± 38.891	180.5 ± 38.891	177.5 ± 38.891
+6 mM NH_4SO_4	192.5 ± 50.205	189.5 ± 48.790	184.5 ± 40.305	181.0 ± 50.912	178.0 ± 41.012
+3 mM NH_4SO_4	194.5 ± 47.376	190.5 ± 62.933	176.0 ± 41.012	184.0 ± 55.154	178.0 ± 38.184
+1.5 mM NH_4SO_4	199.5 ± 48.790	191.5 ± 53.033	181.0 ± 43.841	178.0 ± 53.740	179.0 ± 38.184

TABLE 31

Plasma Product	Pre-Lyo Factor V (%)	Post-Lyo Factor V (%)	4 days at 40° C. Factor V (%)	5 days at 40° C. Factor V (%)	6 days at 40° C. Factor V (%)
Control	78.5 ± 17.678	71.0 ± 0.000	27.0 ± 4.243	37.5 ± 2.121	37.0 ± 1.414
+8 mM NH_4SO_4	69.5 ± 21.920	74.5 ± 0.707	55.5 ± 2.121	55.0 ± 7.071	53.5 ± 2.121
+6 mM NH_4SO_4	75.5 ± 12.021	73.5 ± 2.121	50.0 ± 4.243	55.0 ± 2.828	54.0 ± 0.000
+3 mM NH_4SO_4	68.0 ± 19.799	70.5 ± 2.121	41.0 ± 4.243	43.5 ± 0.707	46.0 ± 0.000
+1.5 mM NH_4SO_4	82.0 ± 4.243	70.5 ± 3.536	35.0 ± 4.243	39.0 ± 1.414	42.5 ± 0.707

TABLE 32

Plasma Product	Pre-Lyo Factor VIII (%)	Post-Lyo Factor VIII (%)	4 days at 40° C. Factor VIII (%)	5 days at 40° C. Factor VIII (%)	6 days at 40° C. Factor VIII (%)
Control	126.0 ± 55.154	83.5 ± 51.619	69.5 ± 53.033	93.5 ± 71.418	62.0 ± 32.527
+8 mM NH_4SO_4	119.0 ± 55.154	156.0 ± 128.693	116.5 ± 98.288	157.5 ± 133.643	87.0 ± 45.255
+6 mM NH_4SO_4	104.0 ± 29.698	147.0 ± 118.794	108.5 ± 95.459	148.0 ± 117.380	87.0 ± 42.426
+3 mM NH_4SO_4	98.5 ± 28.991	137.0 ± 108.894	86.5 ± 71.418	126.0 ± 100.409	76.0 ± 38.184
+1.5 mM NH_4SO_4	103.5 ± 36.062	129.0 ± 106.066	75.5 ± 55.861	109.0 ± 87.681	67.5 ± 33.234

1. A plasma preparation comprising lyophilized, glycine stabilized whole plasma configured for reconstitution with water.

2. The preparation of claim **1**, further comprising at least one protectant selected from the group consisting of calcium chloride, trisodium citrate, HES, ammonium sulfate and combinations thereof.

3. The preparation of claim **1**, further comprising calcium chloride, trisodium citrate, HES or ammonium sulfate.

4. The preparation of claim **3**, wherein said HES is amylopectin-2-hydroxyethylether.

5. The preparation of claim **1**, wherein the water is selected from the group consisting of distilled, deionized, distilled-deionized, autoclaved, sterile saline, ultra pure pathogen free and combinations thereof.

6. The preparation of claim **1**, wherein the plasma is autologous.

7. The preparation of claim **1**, wherein the plasma is allogenic.

8. The preparation of claim **1**, which is reconstituted with water to approximate the original volume of the pre-lyophilized plasma.

9. The preparation of claim **1**, which is reconstituted with water to approximate 50% of the original volume of the pre-lyophilized plasma.

10. A method for preparing freeze-dried plasma comprising

adding glycine to sterile, pathogen free plasma under sterile conditions;

freeze drying said glycine comprising sterile pathogen free plasma under conditions that suppress recrystallization of glycine; and

storing the lyophilized product.

11. The method of claim **10** further comprising:

freezing the plasma by:

loading the plasma at room temperature into a freezable container;

placing the freezable container into a lyophilizer;

freezing the plasma to −4° C. at 2° C. per minute;

holding the temperature for 10 minutes;

freezing the plasma to −40° C. at 1° C. per minute; and

holding the temperature for 120 minutes.